Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan®-10 after bolus injection

British Journal of Clinical Pharmacology

Volumn 47, Issue 6, 1999, Pages 653-660

  Knibbe, Catherijne A J ^a   Voortman, Henk Jan ^a   Aarts, Leon P H J ^a   Kuks, Paul F M ^a   Lange, Rogier ^a   Langemeijer, Han J M ^a   Danhof, Meindert ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Anaesthetics i.v.; Emulsion formulation; Induction characteristics; Pharmacokinetics; Pharmacology; Propofol

Indexed keywords

INTRALIPID; LIPOFUNDIN; PROPOFOL;

ADULT; ANESTHESIA INDUCTION; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; AGED; ANESTHESIA, INTRAVENOUS; ANESTHETICS, INTRAVENOUS; DOUBLE-BLIND METHOD; EMULSIONS; FEMALE; HUMANS; MIDDLE AGED; PROPOFOL;

EID: 0032992191     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00942.x     Document Type: Article

References (36)

1. 1 Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995; 50: 513-559.
2. 2 Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50: 636-657.
3. 3 Boyle WA, Shear JM, White PF, Schuller D. Tolerance and hyperlipidemia during long-term sedation with propofol [abstract]. Anaesthesiology 1990; 73(Suppl. 3A): A245.
4. 4 Cook S, Palma O. Propofol as a sole agent for prolonged infusion in intensive care. J Drug Dev 1989; 2(Suppl. 2): 65-67.
5. 5 Gottardis M, Khünl-Brady KS, Koller W, Sigl G, Hackl JM. Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth 1989; 62: 393-396.
6. 6 Parke TJ, Stevens JE, Rice ASC, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. Br Med J 1992; 305: 613-616.
7. 7 Strickland RA, Murray MJ. Fatal metabolic acidosis in a pedriatic patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med 1995; 23: 405-409.
8. 8 Plötz FB, Waalkens HJ, Verkade HJ, Strengers JLM, Knoester H, Mandema JM. Fatal side-effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care 1996; 24: 724-731.
9. 9 Product information Diprivan®-10. In Repertorium, Edition 1998/1999, eds Zeneca Pharma, Utrecht, The Netherlands: Nefarma & Neprofarm, 1998: 916-918.
10. 10 Glen JB, Hunter SC. Pharmacology of an emulsion formulation of ICI 35868. Br J Anaesth 1984; 56: 617-625.
11. 11 Cummings GC, Dixon J, Kay NH, et al. Dose requirements of ICI 35,868 (Propofol, 'Diprivan') in a new formulation for induction of anaesthesia. Anaesthesia 1984; 39: 1168-1171.
12. 12 Dutta S, Matsumoto Y, Ebling WF. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation. J Pharm Sci 1997; 86: 967-969.
13. 13 Dutta S, Ebling WF. Emulsion formulation reduces propofol dose requirements and enhances safety. Anesthesiology 1997; 87: 1394-1405.
14. 14 Cox EH, Knibbe CAJ, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998; 15: 442-448.
15. 15 Knibbe CAJ, Koster VS, Deneer VHM, Stuurman RM, Kuks PFM, Lange R. Determination of propofol in low volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998; 706: 305-310.
16. 16 Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control 1974; AC-19: 716-723.
17. 17 Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics, Second Edition, eds Gibaldi M, Perrier D, New York: Marcel Dekker, 1982: 409-424.
18. 18 Rutter BV, Morgan M, Lumley J, Owen R. ICI 35868 (Diprivan): a new intravenous induction agent. A comparison with methohexitone. Anaesthesia 1980; 35: 1188-1192.
19. 19 Briggs LP, Clarke RSJ, Watkins J. An adverse reaction to the administration of disoprofol (Diprivan). Anaesthesia 1982; 37: 1099-1101.
20. 20 De Grood PMRM, Coenen LGJ, van Egmond J, Booij LHDJ, Crul JF. Propofol emulsion for induction and maintenance of anaesthesia. A combined technique of general and regional anesthesia. Acta Anaesthesiol Scand 1987; 31: 219-223.
21. 21 Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 1997; 85: 1399-1403.
22. 22 Cockshott ID, Briggs LP, Douglas EJ, White M. Pharmacokinetics of propofol in female patients. Studies using single bolus injections. Br J Anaesth 1987; 59: 1103-1110.
23. 23 Kay NH, Scar JW, Uppington J, Cockshott ID, Douglas EJ. Disposition of propofol in patients undergoing surgery. A comparison in men and women. Br J Anaesth 1986; 58: 1075-1079.
24. 24 Gin T, Gregory MA, Chan K, Buckley, Oh TE. Pharmacokinetics of propofol in women undergoing elective caesarean section. Br J Anaesth 1990; 64: 148-153.
25. 25 Adam HK, Briggs LP, Bahar M, Douglas EJ, Dundee JW. Pharmacokinetic evaluation of ICI 35868 in man. Single induction doses with different rates of injection. Br J Anaesth 1983; 55: 97-103.
26. 26 Chiou WL. New physiologically based methods for calculating the apparent steady-state volume of distribution in pharmacokinetic studies. Int J Clin Pharmacol Ther Toxicol 1982; 20: 255-258.
27. 27 Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I). Clin Pharmacokin 1989; 17: 175-199.
28. 28 Major E, Aun C, Yate PM, et al. Influence of sample site on blood concentrations of ICI 35868. Br J Anaesth 1983; 55: 371-375.
29. 29 Wang YP, Cheng YJ, Fan SZ, Liu CC. Arteriovenous concentration differences of propofol during and after a stepdown infusion. Anesth Analg 1994; 79: 1148-1150.
30. 30 McQuay HJ, Moore RA, Paterson GMC, Adams AP. Plasma fentanyl concentrations and clinical observations during and after operation. Br J Anaesth 1979; 51: 543-550.
31. 31 Campbell GA, Morgan DJ, Kumar K, Crankshaw DP. Extended blood collection period required to define distribution and elimination kinetics of propofol. Br J Clin Pharmacol 1988; 26: 187-190.
32. 32 Elfstrom J. Drug pharmacokinetics in the postoperative period. Clin Pharmacokin 1979; 4: 16-22.
33. 33 Rolly G, Versichelen L, Huyghe L, Mungroop H. Effect of speed of injection on induction of anaesthesia using propofol. Br J Anaesth 1985; 57: 743-746.
34. 34 Klement W, Arndt JO. Pain on injection of propofol; effects of concentrations and diluent. Br J Anaesth 1991; 67: 281-284.
35. 35 Doenicke AW, Roizen MF, Rau J, Kellermann W, Babl J. Reducing pain during propofol injection: the role of the solvent. Anesth Analg 1996; 82: 472-474.
36. 36 Babl J, Doenicke A, Mönch V. New formulation of propofol in an LCT/MCT emulsion. EHP 1995; 1: 15-21.